These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 14983223

  • 1. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
    Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M.
    Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
    Małyszko J, Łebkowska U, Małyszko JS, Myśliwiec M.
    Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2006 Dec; 38(1):105-7. PubMed ID: 16504676
    [Abstract] [Full Text] [Related]

  • 7. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients.
    Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M.
    Nephrology (Carlton); 2007 Jun; 12(3):246-53. PubMed ID: 17498119
    [Abstract] [Full Text] [Related]

  • 8. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 9. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 10. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
    [Abstract] [Full Text] [Related]

  • 11. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
    Santamaría A, Borrell M, Oliver A, Ortín R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J.
    Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
    [Abstract] [Full Text] [Related]

  • 12. Visfatin and endothelial function in dialyzed patients.
    Malyszko J, Malyszko JS, Mysliwiec M.
    Nephrology (Carlton); 2010 Mar; 15(2):190-6. PubMed ID: 20470278
    [Abstract] [Full Text] [Related]

  • 13. Thyroid function, endothelium, and inflammation in hemodialyzed patients: possible relations?
    Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M.
    J Ren Nutr; 2007 Jan; 17(1):30-7. PubMed ID: 17198929
    [Abstract] [Full Text] [Related]

  • 14. Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
    Malyszko J, Malyszko JS, Mysliwiec M.
    Blood Coagul Fibrinolysis; 2002 Oct; 13(7):615-21. PubMed ID: 12439147
    [Abstract] [Full Text] [Related]

  • 15. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J, Suchowierska E, Malyszko JS, Mysliwiec M.
    Perit Dial Int; 2002 Oct; 22(5):582-92. PubMed ID: 12455569
    [Abstract] [Full Text] [Related]

  • 16. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 17. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
    Małyszko J, Suchowierska E, Małyszko JS, Myśliwiec M.
    Kidney Blood Press Res; 2002 Jan; 25(4):240-4. PubMed ID: 12424426
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
    Gumus K, Kadayifcilar S, Eldem B, Ozcebe O.
    Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
    [Abstract] [Full Text] [Related]

  • 19. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
    Paparella D, Semeraro F, Scrascia G, Galeone A, Ammollo CT, Kounakis G, de Luca Tupputi Schinosa L, Semeraro N, Colucci M.
    Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
    [Abstract] [Full Text] [Related]

  • 20. Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome.
    Gursoy T, Tekinalp G, Yurdakok M, Ozcebe O, Korkmaz A, Gurgey A.
    Am J Hematol; 2008 Jan; 83(1):50-3. PubMed ID: 17654683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.